Objective To evaluate whether the classification of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) according to ANCA type (anti-proteinase 3 (PR3) or ...

Objectives To investigate the reliability of elevated titres of antineutrophil cytoplasmic antibody (ANCA) and to identify a cut-off titre in discriminating ... For normally distributed continuous ...

Avacopan is under clinical development by Amgen and currently in Phase III for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). According to GlobalData, Phase III drugs ...

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). According to GlobalData, ...

AIMS To describe the distribution and features of classic polyarteritis nodosa (PAN) and microscopic polyarteritis (MPA) and the importance of antineutrophil cytoplasmic antibody (ANCA) in childhood ...

Rituximab (RTX), an anti-CD20 monoclonal antibody, represents a valuable treatment for anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV). RTX biosimilar CT-P10 (RTX-B) has been ...

In addition, we test antinuclear antibodies by enzyme immune assays as well as by indirect fluorescence (IFA), and individual antibodies to nuclear antigens, anticardiolipin antibodies, and ...

Subsequent investigation showed renal failure and multiple pulmonary nodules. A positive proteinase 3 antineutrophil cytoplasmic antibody test supported the diagnosis of fulminant Wegener’s ...

Perinuclear antinuclear cytoplasmic antibody titres were 1:40 (reference range <1:20, ARUP Laboratories, Utah, USA), MPO antibody was positive at 44 AU/mL (reference range 0–19) and serine protease 3 ...